Who are Rivaroxaban or Marcumar's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rivaroxaban-or-marcumar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rivaroxaban or Marcumar — Competitive Intelligence Brief

Rivaroxaban or Marcumar (Rivaroxaban or Marcumar) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant (Rivaroxaban: direct Factor Xa inhibitor; Marcumar: vitamin K antagonist). Area: Cardiovascular.

marketed Anticoagulant (Rivaroxaban: direct Factor Xa inhibitor; Marcumar: vitamin K antagonist) Factor Xa (Rivaroxaban); Vitamin K epoxide reductase complex (Marcumar) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rivaroxaban or Marcumar (Rivaroxaban or Marcumar) — RWTH Aachen University. Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade, while Marcumar (phenprocoumon) is a vitamin K antagonist that inhibits clotting factor synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rivaroxaban or Marcumar TARGET	Rivaroxaban or Marcumar	RWTH Aachen University	marketed	Anticoagulant (Rivaroxaban: direct Factor Xa inhibitor; Marcumar: vitamin K antagonist)	Factor Xa (Rivaroxaban); Vitamin K epoxide reductase complex (Marcumar)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant (Rivaroxaban: direct Factor Xa inhibitor; Marcumar: vitamin K antagonist) class)

RWTH Aachen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rivaroxaban or Marcumar — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban-or-marcumar. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab